韩国Celltrion
Celltrion公司是基因泰克（Genentech）控股子公司和韩国联合财团于2002年合资成立的韩国最大的生物药物公司。全球第二大单克隆抗体生产企业.Celltrion公司在企业与政府的共同建设下发展卓越，拥有5万升生物反应器，可生产多种产品

Supplying next generation medicines to the world

Celltrion is a biopharmaceutical manufacturing company dedicated to supplying the next generation of biopharmaceutical products to the global community. Our seasoned management team, favorable cost structure and strategic location in the rapidly growing Asian pharmaceutical markets make us an ideal choice for clients seeking world-class contract manufacturing services.

Celltrion's 23-acre manufacturing operation is located at the center of the high-technology park in Songdo New City, a new high-technology complex in the Incheon Metropolitan City , South Korea. The Celltrion facility is in close proximity to both the Incheon International Airport and downtown Seoul. Construction of Celltrion's 50,0000-liter capacity biopharmaceutical manufacturing facility, which is expected to be ready for commercial operation by early 2006, is being designed to comply width the cGMP (current Good Manufacturing Practices) Standards of the U.S. Food and Drug Administration and EMEA. The capacity can be quickly expanded to 150,000 liters based on client demand.

The facility layout wraps the process and critical process support areas in a highly automated, clean, safe, cGMP and regulatory compliant environment. It has been optimized to facilitate the logical flow of personnel, raw materials, in-process products, clean/dirty equipment, and waste removal.

Celltrion's integrated departments and teams, including R&D, engineering, QA/QC, and manufacturing, as well as business services and marketing, work closely together to understand and address the business and technical needs of our partners.

Conceptual design and preliminary engineering were carried out by Fluor Corp., a leading U.S. engineering and design firm. Detailed engineering and construction are being performed by Bioengineering AG of Switzerland and Daewoo Engineering and Construction Co. of Korea.

Celltrion's Mission


Our mission is to generate value on behalf of our clients by managing both the operational and financial risks associated width manufacturing. We do this while being uncompromising on quality, reliability, consistency and service.

We work closely width our clients to develop customized manufacturing solutions and focus on minimizing costs associated width the manufacturing process. Our quality assurance team will ensure that all services meet standards.[redux]



Celltrion History


In the spring of 2002, VaxGen, a California-based biotechnology company, and a group of Korean partners founded what will be the largest biopharmaceutical contract manufacturer in Asia. South Korea was selected for its strategic location, access to a growing pharmaceutical market in the region, established local infrastructure and competitive economics.

A ground-breaking ceremony was held in the spring of 2003. The construction of the facility has been rapid and on schedule.